Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate
Public ClinicalTrials.gov record NCT03582475. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase Ib Trial of Pembrolizumab (MK-3475) With Platinum-Based Chemotherapy in Small Cell/Neuroendocrine Cancers of Urothelium and Prostate
Study identification
- NCT ID
- NCT03582475
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Enrollment
- 15 participants
Conditions and interventions
Conditions
- Bladder Small Cell Neuroendocrine Carcinoma
- Castration-Resistant Prostate Carcinoma
- Metastatic Bladder Urothelial Carcinoma
- Metastatic Urethral Urothelial Carcinoma
- Prostate Carcinoma Metastatic in the Bone
- Prostate Neuroendocrine Neoplasm
- Prostate Small Cell Carcinoma
- Stage III Bladder Cancer American Joint Committee on Cancer ( AJCC) v8
- Stage III Prostate Cancer AJCC v8
- Stage III Urethral Cancer AJCC v8
- Stage IV Bladder Cancer AJCC v8
- Stage IV Prostate Cancer AJCC v8
- Stage IV Urethral Cancer AJCC v8
- Stage IVA Bladder Cancer AJCC v8
- Stage IVB Bladder Cancer AJCC v8
- Ureter Small Cell Carcinoma
- Urothelial Carcinoma
Interventions
- Carboplatin Drug
- Cisplatin Drug
- Docetaxel Drug
- Etoposide Drug
- Pembrolizumab Biological
Drug · Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 10, 2019
- Primary completion
- Nov 30, 2025
- Completion
- Nov 30, 2026
- Last update posted
- Nov 11, 2025
2019 – 2026
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UCLA / Jonsson Comprehensive Cancer Center | Los Angeles | California | 90095 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03582475, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 11, 2025 · Synced May 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03582475 live on ClinicalTrials.gov.